Drug Channels

OCTOBER 2, 2023

This week, I’m rerunning some popular posts while I put the finishing touches on DCI's new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Click here to see the original post from May 2023. d/b/a Drug Channels Institute.

Pharmacy 97

Pharmacy Pharmaceuticals Marketing Drugs 97

Drug Channels

AUGUST 8, 2023

on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. Recently, a bipartisan group of six U.S. Click here to read the full letter. I submitted a 14-page letter, which you can read below. I shared my $0.02

Pharmacy 96

Pharmacy Hospitals Drugs Pharmaceuticals 96

Drug Channels

APRIL 12, 2022

What’s more, taxpayers—via Medicare and Medicaid—will continue to crowd out the private insurance market. Thus, the government actuaries expect that pharmaceuticals will not be the key driver of U.S. Read more » Copyright © 2006-2022 Pembroke Consulting, Inc. healthcare spending. healthcare spending growth. to 1:30 p.m.

Pharmacy 98

Pharmacy Drugs Government Pharmaceuticals 98

Drug Channels

OCTOBER 3, 2023

This week, I’m rerunning some popular posts while I put the finishing touches on our new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. CVS Health launched Cordavis, a new subsidiary that will market a private label, low-list-price version of Sandoz’ Hyrimoz. The Humira biosimilar market has arrived!

Biosimilars 98

Biosimilars Pharmacy Marketing Pharmaceuticals 98

Drug Channels

MAY 24, 2023

In recent years, each of these companies has launched new group purchasing organizations (GPOs) to further consolidate the number of covered lives in rebate negotiations with pharmaceutical manufacturers. Read more » Copyright © 2006-2023 Pembroke Consulting, Inc. to 1:30 p.m. Click here to learn more and register.

Pharmacy 98

Pharmacy Pharmaceuticals Marketing Drugs 98

Drug Channels

OCTOBER 2, 2024

This week, I’m rerunning some popular posts while we put the finishing touches on DCI’s new 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. The 340B contract pharmacy market shows little sign of slowing down. For an updated look at what’s next for the 340B contract pharmacy market, join Adam J.

Pharmacy 52

Pharmacy Specialty Pharmacies Hospitals Marketing 52

Drug Channels

OCTOBER 21, 2024

Stop running in circles—It’s time to unlock proven strategies to propel market access. A program driven by market dynamics and led by champions of channel strategy, join your peers now to master the complexities of pharmacy and distribution models to accelerate market access—It's all happening December 10-12.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Marketing Compliance 98

Drug Channels

OCTOBER 5, 2023

This week, I’m rerunning some popular posts while I put the finishing touches on DCI's new 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. During the full 90-minute webinar, I discussed seven crucial risks that could disrupt this market along with many other aspects of this emerging market.

Pharmaceuticals 97

Pharmaceuticals Drugs Marketing 97

Drug Channels

MARCH 15, 2022

Prescription Market (press release) We’re offering special discounted pricing if you order before March 28, 2022. As always, we have updated all market and industry data with the most current information available, including our annual analyses of the market positions of the largest pharmacies, specialty pharmacies, and PBMs.

Pharmacy 98

Pharmacy Specialty Pharmacies Licensing Licensing 98

Drug Channels

JULY 11, 2022

President and CEO, National Pharmaceutical Council Julie Ritchie Wagner, Senior Assistant General Counsel, Head of Global Ethics, Compliance, and Enforcement Legal Policy, PhRMA Joel White, Founder and President, Horizon Government Affairs Charlene Keller Fullmer, Assistant U.S. Copyright © 2006-2022 Pembroke Consulting, Inc.

Specialty Pharmacies 98

Specialty Pharmacies Pharmacy Biosimilars Compliance 98

Alta Sciences

MARCH 4, 2025

The CCALC is a grassroots organization that was founded by several pharmaceutical industry members seeking clarity around the conduct of abuse and dependence potential assessments for novel drugs in development. This was in 2006, at a time when the FDA guidances on these topics had not yet been published.

Clinical Trials 52

Clinical Trials FDA Drug Development Trials 52

The Pharma Data

AUGUST 19, 2020

Multiple Attorney Generals from across the US are seeking billions of dollars in damages to settle opioid cases against major pharmaceutical manufacturers and distributors. . New York State also says Teva made 20% of all opioids distributed from 2006 to 2014 in the region and marketed its products for off-label uses.

Pharmaceuticals 52

Pharmaceuticals Doctors International FDA 52

Drug Channels

MAY 9, 2022

Emily Phillips, Reimbursement, Patient Advocate, & Government Affairs Leader Melissa Beatty, Director, Patient Services and Reimbursement, CTI Bio Pharma Chad Bower, Executive Director, Field Reimbursement & Oncology Solutions, US Market Access, Daiichi Sankyo, Inc. Copyright © 2006-2022 Pembroke Consulting, Inc. Attorney, U.S.

Specialty Pharmacies 75

Specialty Pharmacies Pharmacy Pharmaceuticals Government 75

The Pharma Data

OCTOBER 19, 2020

20, 2020 /PRNewswire/ — CNS PHARMACEUTICALS AG , Inc. manufacturer, Pharmaceutics International, Inc. (“Pii”), has completed the manufacturing process for Berubicin Drug Product, its lead drug candidate for the treatment of glioblastoma multiforme (GBM), an aggressive form of brain cancer currently considered incurable.

Clinical Trials 52

Clinical Trials Trials Pharmaceuticals Treatment 52

Drug Channels

OCTOBER 23, 2023

A program driven by market dynamics and led by champions of channel strategy, join now to master the complexities of pharmacy and distribution models to accelerate market access –It's all happening December 11-13, 2023. Why should you attend this pivotal event? How is health policy affecting the distribution channel?

Pharmacy 75

Pharmacy Biosimilars Marketing Production 75

Drug Channels

SEPTEMBER 12, 2023

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. As always, we have updated all market and industry data with the most current information available. Copyright © 2006-2023 Pembroke Consulting, Inc.

Pharmaceuticals 40

Pharmaceuticals Pharmacy Biosimilars Licensing 40

Drug Channels

OCTOBER 13, 2020

I am pleased to announce our new 2020–21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. The 2020–21 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors is the only resource of its kind available anywhere. healthcare system.

Pharmaceuticals 40

Pharmaceuticals Licensing Licensing Pharmacy 40

Drug Channels

MARCH 19, 2023

Copyright © 2006-2023 Pembroke Consulting, Inc. Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). d/b/a Drug Channels Institute. Drug Channels® is a registered trademark of Pembroke Consulting, Inc.

Science 75

Science Government Pharmaceuticals Drugs 75

Drug Channels

MAY 22, 2023

WHAT YOU WILL LEARN As expensive specialty therapies come to dominate drug spending, pharmaceutical manufacturers are paying a growing share of patents’ out-of-pocket costs for these prescriptions. Copyright © 2006-2023 Pembroke Consulting, Inc. This event is part of The Drug Channels 2023 Video Webinar Series.

Pharmacy 97

Pharmacy Drugs Marketing Therapies 97

Drug Channels

OCTOBER 10, 2023

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. we analyze the IRA’s likely consequences for wholesalers and the overall pharmaceutical business. In Subsection 6.5.1.,

Pharmaceuticals 40

Pharmaceuticals Specialty Pharmacies Pharmacy Biosimilars 40

Drug Channels

NOVEMBER 4, 2020

on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations. For your reference, I also include links to published comments from the American Hospital Association and the Pharmaceutical Research and Manufacturers of America. I shared my $0.02 d/b/a Drug Channels Institute.

Pharmacy 52

Pharmacy Hospitals Pharmaceuticals Marketing 52

Drug Channels

JULY 23, 2024

It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. Insulin has been the first to deflate—and the Humira biosimilar market may be next. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. You can find links to each company’s data below.

Biosimilars 52

Biosimilars Pharmaceuticals Production Drugs 52

Drug Channels

SEPTEMBER 18, 2023

Attorney’s Office for the Eastern District of Pennsylvania Suzanne Marinakos, Director, Patient Services Operations- Rare Disease , Novo Nordisk Snigdha Santra, Director, Business Insights and Strategy , Chugai Pharmaceuticals Kinshuk Saxena, Pharm.D., Copyright © 2006-2023 Pembroke Consulting, Inc. d/b/a Drug Channels Institute.

Compliance 75

Compliance Pharmaceuticals Drugs Disease 75

Drug Channels

SEPTEMBER 23, 2024

View the Complete Agenda Book Your Place The complex components of gross-to-net management requires cross-functional collaboration in order to effectively develop sound accrual estimates, proper forecasting, optimized pricing and contracting models and accurate financial reporting, all with minimal disruption to market access strategies.

Compliance 52

Compliance Pharmaceuticals Marketing Government 52

Drug Channels

MARCH 26, 2021

on the overall market, explained channel distortions from 340B contract pharmacies, and offered some policy recommendations. For your reference, I also include links to published comments from the American Hospital Association and the Pharmaceutical Research and Manufacturers of America. I shared my $0.02 d/b/a Drug Channels Institute.

Pharmacy 52

Pharmacy Hospitals Pharmaceuticals Drugs 52

Agency IQ

APRIL 12, 2024

The vote is in: The European Parliament has adopted the compromise pharmaceutical legislation This week, the European Parliament voted to adopt the compromise texts of both the revised pharmaceutical directive and regulation presented by Parliament’s health committee in March 2024. has a strong voice in the world. citizens; 2.

Pharmaceuticals 40

Pharmaceuticals Regulations Packaging Marketing 40

Drug Channels

MAY 21, 2024

WHAT YOU WILL LEARN The federal 340B Drug Pricing Program continues to grow much more quickly than the overall pharmaceutical market. DCI estimates that 340B discounts equated to more than 17% of total value of gross-to-net reductions for brand-name pharmaceuticals. Pharmacies and Pharmacy Benefit Managers. All rights reserved.

Pharmacy 52

Pharmacy Drugs Pharmaceuticals Marketing 52

Drug Target Review

JUNE 19, 2024

Also, many companies never reached the point where they received validation from big pharmaceutical companies. From 2002 until 2004, Mr Culley was Director of Business Development and Marketing for Immusol, Inc. Mr Culley served on the Board of Orphagen Pharmaceuticals, Inc. from May 2017 until December 2022.

Therapies 84

Therapies Small Molecule Pharmaceutical Companies Molecular Biology 84

Drug Channels

MARCH 14, 2022

The Summit will again welcome the full spectrum of organizations working in the pharmacy, life sciences & patient services market. Copyright © 2006-2022 Pembroke Consulting, Inc. Send it to connect@asembiasummit.com. for consideration. Drug Channels, or any of its employees. d/b/a Drug Channels Institute.

Specialty Pharmacies 74

Specialty Pharmacies Pharmacy FDA Science 74

The Pharma Data

JULY 22, 2021

Teva Pharmaceutical Industries Ltd. Sven has played an integral role in optimizing Teva’s vast global portfolio, in the R&D pipeline strategy, and leading global marketing teams including responsibility for AJOVY ® , AUSTEDO ® and Digital Health. NYSE and TASE: TEVA) today announced changes to its leadership team.

International 52

International Marketing Pharmaceuticals Engineering 52

Drug Channels

SEPTEMBER 21, 2020

Executive Director , National Association of Specialty Pharmacy (NASP) David Kowalsky, Director, Market Access and Patient Services , EyePoint Pharmaceuticals Andrew Gettinger, Chief Clinical Officer , ONC at US Department of Health & Human Services And more! Copyright © 2006-2020 Pembroke Consulting, Inc. Arquette, R.Ph.,

Specialty Pharmacies 52

Specialty Pharmacies Pharmacy Pharmaceuticals Production 52

Drug Channels

SEPTEMBER 3, 2024

© 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Register Today. Download the brochure. The content of Sponsored Posts does not necessarily reflect the views of HMP Omnimedia, LLC, Drug Channels Institute, its parent company, or any of its employees. All rights reserved.

Pharmaceutical Companies 52

Pharmaceutical Companies Pharmaceuticals Government Regulations 52

Drug Channels

OCTOBER 30, 2023

Copyright © 2006-2023 Pembroke Consulting, Inc. The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees. To find out how you can promote an event on Drug Channels, please contact Paula Fein (paula@drugchannels.net). d/b/a Drug Channels Institute.

Pharmaceutical Companies 74

Pharmaceutical Companies Regulations Pharmaceuticals Drugs 74

Drug Channels

JULY 20, 2021

The 340B Drug Pricing Program continues to expand far more quickly than the overall pharmaceutical market—and some channels are benefiting more than others. That’s about six times faster than the overall mail and specialty market. Consequently, specialty pharmacies have gained a greater share of the 340B market.

Specialty Pharmacies 40

Specialty Pharmacies Pharmacy Marketing Pharmaceuticals 40

Drug Channels

DECEMBER 1, 2020

During 2020, the COVID-19 pandemic disrupted every aspect of the pharmaceutical channel—and our lives. Pharmacy and healthcare provider markets experienced unprecedented volatility. Pharmaceutical wholesalers have maintained shipments and operational capacity. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

Pharmacy 40

Pharmacy Drugs Vaccine Pharmaceuticals 40

Drug Channels

AUGUST 11, 2020

Time for our annual update on pricing at five of the largest pharmaceutical manufacturers—Eli Lilly, Janssen, Merck, Novartis, and Sanofi. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc. You can find links to each company’s data below. When rebates and discounts were factored in, drug prices declined—or grew slowly—in 2019.

Government 52

Government Pharmaceuticals Drugs Marketing 52

The Premier Consulting Blog

JULY 9, 2023

These evaluations include the active pharmaceutical ingredient (API), also known as the drug substance, and the drug product (formulated product). ICH M7 (R1) Assessment and control of DNA reactive (mutagenic) impurities in pharmaceuticals to limit potential carcinogenic risk – Scientific guideline. link] ICH M7 (R2)- Q&A.

Small Molecule 52

Small Molecule DNA Drugs Clinical Development 52